2566-31-6 Usage
Uses
Used in Pharmaceutical Research and Development:
DIPROPYLGLYCINE is used as a research compound for its potential therapeutic effects in treating neurological disorders such as epilepsy and neuropathic pain. It is valued for its capacity to be further explored and developed into pharmaceuticals due to these potential applications.
Used in Neurological Disorder Treatment:
DIPROPYLGLYCINE is used as a potential treatment for neurological disorders, specifically targeting conditions like epilepsy and neuropathic pain. Its role in this application is due to ongoing research that suggests it may have beneficial effects on these conditions.
Used in Analgesic and Anti-Inflammatory Applications:
DIPROPYLGLYCINE is used as an analgesic and anti-inflammatory agent, given its potential to alleviate pain and reduce inflammation. The exploration of these effects is part of the broader research into its clinical utility.
While the exact mechanisms of action and clinical usage of DIPROPYLGLYCINE are still under investigation, its role in these applications highlights the significance of ongoing research in unlocking its full therapeutic potential.
Check Digit Verification of cas no
The CAS Registry Mumber 2566-31-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,5,6 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 2566-31:
(6*2)+(5*5)+(4*6)+(3*6)+(2*3)+(1*1)=86
86 % 10 = 6
So 2566-31-6 is a valid CAS Registry Number.
InChI:InChI=1/C8H17NO2/c1-3-5-8(9,6-4-2)7(10)11/h3-6,9H2,1-2H3,(H,10,11)
2566-31-6Relevant academic research and scientific papers
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Cα,α-dialkylated amino acids
Arduin, Marika,Spagnolo, Barbara,Calo, Girolamo,Guerrini, Remo,Carra, Giacomo,Fischetti, Carmela,Trapella, Claudio,Marzola, Erika,McDonald, John,Lambert, David G.,Regoli, Domenico,Salvadori, Severo
, p. 4434 - 4443 (2008/03/13)
Previous structure-activity and NMR studies on nociceptin/orphanin FQ (N/OFQ) demonstrated that Aib substitution of Ala7 and/or Ala11 increases the peptide potency through an alpha helix structure induction mechanism. On these bases we synthesised and evaluated pharmacologically in the mouse vas deferens assay a series of N/OFQ-NH2 analogues substituted in position 7 and 11 with Cα,α-disubstituted cyclic, linear and branched amino acids. None of the 20 novel N/OFQ analogues produced better results than [Aib7]N/OFQ-NH2. Thus, this substitution was combined with other chemical modifications known to modulate peptide potency and/or efficacy generating compound 21 [Nphe1Aib7Arg14Lys15]N/OFQ-NH2 (coded as UFP-111), compound 22 [(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-112) and compound 23 [Phe1Ψ(CH2-NH)Gly2(pF)Phe4Aib7Arg14Lys15]N/OFQ-NH2 (UFP-113). These novel peptides behaved as highly potent NOP receptor ligands showing full (UFP-112) and partial (UFP-113) agonist and pure antagonist (UFP-111) activities in a series of in vitro functional assays performed on pharmacological preparations expressing native as well as recombinant NOP receptors.
